Apyx Medical Corporation updated financial guidance for the year ending December 31, 2022. For the period the company announced that total revenue in the range of $52.5 million to $59.0 million, representing growth of 8% to 22% year-over-year, compared to total revenue of $48.5 million for the year ended December 31, 2021. The Company's prior guidance range for total revenue was $50.0 million to $63.0 million, representing growth of 3% to 30% year-over-year.

Net loss attributable to stockholders in the range of $19.0 million to $14.7 million, compared to net loss attributable to stockholders of $15.2 million for the year ended December 31, 2021. The Company's prior guidance range for net loss attributable to stockholders was $21.1 million to $12.1 million.